Q3 2025 Relmada Therapeutics Inc Earnings Call Transcript

Nov 13, 2025 / 09:30 PM GMT

Release Date Price: $3.88 (-0.77%)

Transcript 8-K10-Q

Key Points

Positve

Relmada Therapeutics Inc (RLMD) reported a 92% overall response rate in their phase 2 study of NDVO1 for non-muscle invasive bladder cancer (NMIBC), with favorable safety outcomes.
The company secured FDA alignment on key elements of the phase 3 program for NDVO1, which could lead to two distinct registration tracks.
Relmada Therapeutics Inc (RLMD) completed a $100 million underwritten financing, providing resources to support operations into 2028.
The company plans to initiate two separate registrational studies for NDVO1 and a phase 2 study for Sopranolol in Prader-Willi syndrome in the first half of 2026.
Relmada Therapeutics Inc (RLMD) has expanded its clinical team and established a clinical advisory board with prominent leaders in NMIBC to guide their pivotal program.

Negative

Relmada Therapeutics Inc (RLMD) reported a net loss of $10.1 million for the third quarter of 2025, although this was an improvement from the previous year.
The company's cash equivalents and short-term investments decreased to $13.9 million as of September 30, 2025, from $44.9 million at the end of 2024.
Research and development expenses decreased significantly, which may indicate a slowdown in certain areas of development.
The company faces challenges in pricing and market penetration for NDVO1, as it competes with existing therapies like J&J's and Lexo's products.
There are operational hurdles in the community setting for the administration of NDVO1, which may limit its initial adoption outside academic centers.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

RLMD.OQ - Relmada Therapeutics Inc
Q3 2025 Relmada Therapeutics Inc Earnings Call
Nov 13, 2025 / 09:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good afternoon and welcome to Ramalda Therapeutics 3rd quarter 2025 earnings conference call.

At this time, all participants are in a listen-only mode.

After the prepared remarks, we will conduct a question-and-answer session.

To ask a question, please press star and one.

As a reminder, this conference call is being recorded and will be available for replay on the Romade website.

I would now like to turn the call over to Brian Ritchie of Life Sci Advisors. Please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Good

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.